An Ascending Single Dose Study of the Pharmacokinetics, Safety and Tolerability of Hemay005 in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Hemay 005 (Primary)
- Indications Psoriasis
- Focus Adverse reactions; First in man
- Sponsors Tianjin Hemay Biotech
- 10 Oct 2017 Planned End Date changed from 1 Mar 2018 to 1 May 2018.
- 10 Oct 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
- 07 Jan 2017 New trial record